Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
April 02 2024 - 1:41PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
FILE NUMBER |
001-36763 |
CUSIP
NUMBER |
404124307 |
(Check
One): |
☒ |
Form
10-K |
☐ |
Form
20-F |
☐ |
Form
11-K |
☐ |
Form
10-Q |
☐ |
Form
N-SAR |
☐ |
Form
N-CSR |
For
Period Ended: December 31, 2023
|
☐ |
Transition
Report on Form 10-K |
|
☐ |
Transition
Report on Form 20-F |
|
☐ |
Transition
Report on Form 11-K |
|
☐ |
Transition
Report on Form 10-Q |
|
☐ |
Transition
Report on Form N-SAR |
For
the Transition Period Ended: ______
Nothing
in this form shall be construed to imply that the Commission has
verified
any information contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
INNOVEREN SCIENTIFIC,
INC. |
Full
Name of Registrant |
|
H-CYTE,
INC. |
Former
Name if Applicable |
|
201
E KENNEDY BLVD, SUITE 700 |
Address
of Principal Executive Office (Street and Number) |
|
TAMPA,
FL 33602 |
City,
State and Zip Code |
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
|
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof
will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-Q, 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof, could
not be filed within the prescribed time period.
The
registrant has experienced delays in completing its Annual Report on Form 10-K for the year ended December 31, 2023, within the prescribed
time period, due to delays in assembling the financial information required to be reviewed by the registrant’s independent auditor,
and in completing the accounting of certain transactions affecting the registrant. The delay could not be eliminated without unreasonable
effort or expense.
The
registrant plans to file its Annual Report on Form 10-K for the year ended December 31, 2023, on or before the fifteenth day following
the prescribed due date.
PART
IV— OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
|
Jeremy
Daniel |
|
844
|
|
633-6839 |
|
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). Yes ☒ No ☐ |
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
Yes
☒ No ☐ |
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
The Company expects to report significantly
lower revenues from operation as a result of the Company’s decision to close its remaining clinics during the first quarter of
the fiscal year ended December 31, 2023.
Innoveren Scientific,
Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
April 2, 2024 |
By: |
/s/
Jeremy Daniel |
|
|
Jeremy
Daniel |
|
|
Chief
Financial Officer |
H CYTE (QB) (USOTC:HCYT)
Historical Stock Chart
From Apr 2024 to May 2024
H CYTE (QB) (USOTC:HCYT)
Historical Stock Chart
From May 2023 to May 2024